

Monique Gangloff

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/541267/publications.pdf>

Version: 2024-02-01

36
papers

3,183
citations

257450

24
h-index

315739

38
g-index

40
all docs

40
docs citations

40
times ranked

5006
citing authors

#	ARTICLE	IF	CITATIONS
1	Saturation of acyl chains converts cardiolipin from an antagonist to an activator of Toll-like receptor-4. <i>Cellular and Molecular Life Sciences</i> , 2019, 76, 3667-3678.	5.4	31
2	ILV-6 Inhibits NF- κ B Responses in <i>Drosophila</i> . <i>Viruses</i> , 2019, 11, 409.	3.3	11
3	Immunogenicity Testing of Lipidoids In Vitro and In Silico: Modulating Lipidoid-Mediated TLR4 Activation by Nanoparticle Design. <i>Molecular Therapy - Nucleic Acids</i> , 2018, 11, 159-169.	5.1	27
4	Three-tier regulation of cell number plasticity by neurotrophins and Tolls in <i>Drosophila</i> . <i>Journal of Cell Biology</i> , 2017, 216, 1421-1438.	5.2	32
5	Toll-like receptor 2 promiscuity is responsible for the immunostimulatory activity of nucleic acid nanocarriers. <i>Journal of Controlled Release</i> , 2017, 247, 182-193.	9.9	13
6	Peptidoglycan-Sensing Receptors Trigger the Formation of Functional Amyloids of the Adaptor Protein Imd to Initiate <i>Drosophila</i> NF- κ B Signaling. <i>Immunity</i> , 2017, 47, 635-647.e6.	14.3	63
7	Bioinformatic Analysis of Toll-Like Receptor Sequences and Structures. <i>Methods in Molecular Biology</i> , 2016, 1390, 29-39.	0.9	3
8	Critical residues involved in Toll-like receptor 4 activation by cationic lipid nanocarriers are not located at the lipopolysaccharide-binding interface. <i>Cellular and Molecular Life Sciences</i> , 2015, 72, 3971-3982.	5.4	28
9	Assembly and localization of Toll-like receptor signalling complexes. <i>Nature Reviews Immunology</i> , 2014, 14, 546-558.	22.7	653
10	Identification of Key Residues That Confer <i>Rhodobacter sphaeroides</i> LPS Activity at Horse TLR4/MD-2. <i>PLoS ONE</i> , 2014, 9, e98776.	2.5	17
11	The molecular basis for recognition of bacterial ligands at equine TLR2, TLR1 and TLR6. <i>Veterinary Research</i> , 2013, 44, 50.	3.0	32
12	Liesegang-like patterns of Toll crystals grown in gel. <i>Journal of Applied Crystallography</i> , 2013, 46, 337-345.	4.5	2
13	Functional Insights from the Crystal Structure of the N-Terminal Domain of the Prototypical Toll Receptor. <i>Structure</i> , 2013, 21, 143-153.	3.3	13
14	Cytokine Spätzle binds to the <i>Drosophila</i> immunoreceptor Toll with a neurotrophin-like specificity and couples receptor activation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 20461-20466.	7.1	36
15	Allergens as Immunomodulatory Proteins: The Cat Dander Protein Fel d 1 Enhances TLR Activation by Lipid Ligands. <i>Journal of Immunology</i> , 2013, 191, 1529-1535.	0.8	85
16	Different dimerisation mode for TLR4 upon endosomal acidification?. <i>Trends in Biochemical Sciences</i> , 2012, 37, 92-98.	7.5	65
17	What the Myddosome structure tells us about the initiation of innate immunity. <i>Trends in Immunology</i> , 2011, 32, 104-109.	6.8	155
18	LPS ligand and culture additives improve production of monomeric MD-1 and 2 in <i>Pichia pastoris</i> by decreasing aggregation and intermolecular disulfide bonding. <i>Protein Expression and Purification</i> , 2011, 76, 173-183.	1.3	3

#	ARTICLE	IF	CITATIONS
19	Molecular Mechanism That Induces Activation of SpÄtzle, the Ligand for the Drosophila Toll Receptor. <i>Journal of Biological Chemistry</i> , 2010, 285, 19502-19509.	3.4	72
20	The molecular basis of the host response to lipopolysaccharide. <i>Nature Reviews Microbiology</i> , 2010, 8, 8-14.	28.6	303
21	Bioinformatic Analysis of Toll-Like Receptor Sequences and Structures. <i>Methods in Molecular Biology</i> , 2009, 517, 69-79.	0.9	4
22	Cleaved thioredoxin fusion protein enables the crystallization of poorly soluble ERÎ± in complex with synthetic ligands. <i>Acta Crystallographica Section F: Structural Biology Communications</i> , 2008, 64, 54-57.	0.7	7
23	Baseless Assumptions: Activation of TLR9 by DNA. <i>Immunity</i> , 2008, 28, 293-294.	14.3	10
24	Elucidation of the MD-2/TLR4 Interface Required for Signaling by Lipid IVa. <i>Journal of Immunology</i> , 2008, 181, 1245-1254.	0.8	134
25	Structural Insight into the Mechanism of Activation of the Toll Receptor by the Dimeric Ligand SpÄtzle. <i>Journal of Biological Chemistry</i> , 2008, 283, 14629-14635.	3.4	67
26	Structure of Toll-Like Receptors. <i>Handbook of Experimental Pharmacology</i> , 2008, , 181-200.	1.8	20
27	Role of the SpÄtzle Pro-domain in the Generation of an Active Toll Receptor Ligand. <i>Journal of Biological Chemistry</i> , 2007, 282, 13522-13531.	3.4	48
28	Structure and Function of Toll Receptors and Their Ligands. <i>Annual Review of Biochemistry</i> , 2007, 76, 141-165.	11.1	562
29	Toll-like receptors as molecular switches. <i>Nature Reviews Immunology</i> , 2006, 6, 693-698.	22.7	160
30	Conserved mechanisms of signal transduction by Toll and Toll-like receptors. <i>Journal of Endotoxin Research</i> , 2005, 11, 294-298.	2.5	6
31	Ligand-Receptor and Receptor-Receptor Interactions Act in Concert to Activate Signaling in the Drosophila Toll Pathway. <i>Journal of Biological Chemistry</i> , 2005, 280, 22793-22799.	3.4	69
32	MD-2: the Toll ?gatekeeper? in endotoxin signalling. <i>Trends in Biochemical Sciences</i> , 2004, 29, 294-300.	7.5	95
33	Overexpression, Purification, and Crystal Structure of Native ERÎ± LBD. <i>Protein Expression and Purification</i> , 2001, 22, 165-173.	1.3	81
34	Different ligands-different receptor conformations: Modeling of the hER? LBD in complex with agonists and antagonists. <i>Medicinal Research Reviews</i> , 2001, 21, 523-539.	10.5	34
35	Crystal Structure of a Mutant hERÎ± Ligand-binding Domain Reveals Key Structural Features for the Mechanism of Partial Agonism. <i>Journal of Biological Chemistry</i> , 2001, 276, 15059-15065.	3.4	125
36	Estrogen receptor transcription and transactivation Structure-function relationship in DNA- and ligand-binding domains of estrogen receptors. <i>Breast Cancer Research</i> , 2000, 2, 353-9.	5.0	110